← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV25행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyCurated CorestaleApproved
Golimumab (Golimumab)
Belfast Health and Social Care Tru…·Chronic Nonbacterial Osteomyelitis
80 trials·t½ 3 h
Overview
Program
Golimumab
Overview
Company
Belfast Health and Social Care Trust
Overview
Modality
ANTIBODY
Overview
Target
Chronic Nonbacterial Osteomyelitis
Overview
Indication
Psoriatic Arthritis; Psoriasis
Overview
Phase
APPROVED
Overview
Status
DISCONTINUED
Overview
Content status
Curated Core
Overview
Data Confidence
Data Confidence · High
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
Positioning
Key differentiator
Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis
MoA
Mechanism
s and infections appeared limited
MoA
Biomarker
biomarker, endoscopic, and histological outcomes were evaluated at weeks 16 and 52
PK/PD
Half-life
3 h
PK/PD
Species
Cynomolgus monkey, NHP, Marmoset
PK/PD
Animal (cat.)
Human, NHP
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Cynomolgus monkey, NHP, Marmoset
Toxicology
Animal (cat.)
Human, NHP
Toxicology
Major finding
Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.. Evidence on golimumab for ulcerative colitis (UC) is scarce in Latin America. We aimed to assess the real-world effectiveness and safety of golimumab in a multicenter Chilean cohort. We conducted a retrospective, observational study including adult patients with moderate-to-severe UC treated…
Clinical
Safety signal
Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.. Evidence on golimumab for ulcerative colitis (UC) is scarce in Latin America. We aimed to assess the real-world effectiveness and safety of golimumab in a multicenter Chilean cohort. We conducted a retrospective, observational study including adult patients with moderate-to-severe UC treated…
Clinical
Result source
ClinicalTrials.gov NCT04200833
Clinical
Program phase
APPROVED
Clinical
Trial ref
NCT04200833